Fibrosis is characterized by the excessive deposition of extracellular matrix and crosslinked proteins, in particular collagen and elastin, leading to tissue stiffening and disrupted organ function. Lysyl oxidases are key players during this process, as they initiate collagen crosslinking through the oxidation of the ε-amino group of lysine or hydroxylysine on collagen side-chains, which subsequently dimerize to form immature, or trimerize to form mature, collagen crosslinks. The role of LOXL2 in fibrosis and cancer is well documented, however the specific enzymatic function of LOXL2 and LOXL3 during disease is less clear. Herein, we describe the development of PXS-5153A, a novel mechanism based, fast-acting, dual LOXL2/LOXL3 inhibitor, which was used to interrogate the role of these enzymes in models of collagen crosslinking and fibrosis. PXS-5153A dose-dependently reduced LOXL2-mediated collagen oxidation and collagen crosslinking in vitro. In two liver fibrosis models, carbon tetrachloride or streptozotocin/high fat diet-induced, PXS-5153A reduced disease severity and improved liver function by diminishing collagen content and collagen crosslinks. In myocardial infarction, PXS-5153A improved cardiac output. Taken together these results demonstrate that, due to their crucial role in collagen crosslinking, inhibition of the enzymatic activities of LOXL2/LOXL3 represents an innovative therapeutic approach for the treatment of fibrosis.
| INTRODUCTION
Fibrosis is a progressive disease characterized by extensive scarring and tissue stiffening, which develop from chronic tissue damage and incessant wound-healing processes. [1] [2] [3] During fibrosis, the excessive deposition, accumulation and crosslinking of collagen causes more lesions to mature, resulting in scarring and, potentially, irreversibility of disease. Fibrosis can develop in nearly any organ and is an important driver of end-stage organ failure and mortality in a number of chronic diseases. 4, 5 development of effective therapeutic avenues that halt or reverse disease progression is urgently required.
In healthy tissues, collagens play a key role by providing strength, stability and integrity. 6 These properties are based on a highly organized molecular structure in which three collagen chains are interwoven into a triple helix. 6 In addition, collagen fibrils are further strengthened by covalent crosslinks formed enzymatically between the collagen molecules. 6, 7 This process has been confirmed to be driven by lysyl oxidases, as when enzymatically active LOX was incubated (in vitro) with purified collagen it resulted in dihydroxylysinonorleucine (DHLNL) as well as pyridinoline (PYD) formation. 8 Specifically, lysyl oxidases oxidatively deaminate lysine and hydroxylysine residues in the telopeptide domains of the collagen molecule to form the corresponding aldehydes (allysines or hydroxyallysines) ( Figure S1 ). Lysyl oxidases constitute a family of copper-dependent amine oxidases comprised of five members, lysyl oxidase (LOX) and lysyl oxidase-like 1-4 (LOXL 1-4). 2 They show a high degree of homology in the catalytic carboxy terminal end and more divergence in the rest of the sequence. 12 Lysyl oxidases regulate many biological processes including extracellular matrix (ECM) stabilization, cellular growth and homeostasis. Their protein expression has been positively correlated with fibrotic diseases in many different tissues including liver, lung and kidney. [13] [14] [15] [16] In addition, certain members of the family -in particular LOX and LOXL2-have been widely associated with cancer progression and metastasis. 13, 17, 18 Early research with a functional antibody for LOXL2 (AB0023), demonstrated efficacy in various pre-clinical models of fibrosis and cancer. 13 Recently, PAT-1251 a selective small molecule inhibitor of LOXL2 also demonstrated potential as an anti-fibrotic agent in pre-clinical models. 19 Although the primary role of this family of enzymes is ECM remodelling, a number of extra-and intracellular functions have also been reported that are independent of the enzymatic activity. Extracellularly, LOXL2 has been shown to signal through β-integrin in cancer-associated fibroblasts 20 and intracellularly, LOXL2
and LOXL3 have been associated with epithelial to mesenchymal transition (EMT). [21] [22] [23] Additionally, LOXL2 is a key player for heterochromatin formation via Snail-dependent mechanisms. 21, 22, 24 Moreover, one study showed that LOXL2 is a negative regulator of Notch1 transcription, thereby attenuating epidermal differentiation. 25 Despite the extensive body of work on lysyl oxidases and the considerable therapeutic potential of LOXL2 and LOXL3 inhibition, no studies have provided unequivocal evidence for the relationship between the enzymatic activities of LOXL2/LOXL3, and the reduction of crosslinks resulting in therapeutic benefits in models of fibrosis. Herein, we set out to develop PXS-5153A, an innovative small molecule inhibitor with complete LOXL2/LOXL3 enzymatic inhibition -unlike the currently available antibody (simtuzimab)-with faster onset and higher potency for LOXL2/ LOXL3 than the small molecule inhibitor racemate of PAT-1251.
Using PXS-5153A, we were able to dissect the enzymatic function of LOXL2 and LOXL3 on the formation of different crosslink subtypes during fibrosis and examine the relevance of LOXL2/LOXL3 inhibition on disease severity as well as organ function recovery.
| MATERIALS AND METHODS

| Fluorometric enzymatic activity assays
The measurement of the enzymatic activity of all lysyl oxidase family members was based on the detection of hydrogen peroxide with an Amplex-Red oxidation assay, as described in Zhou et al 26 Recombinant human semicarbazide sensitive amine oxidase (SSAO/VAP1), diamine oxidase (DAO) and monoamine oxidases A and B (MAO-A and MAO-B) assays were performed as previously described. 27 For detailed enzymatic procedures, see supporting information.
| Off-target activity
PXS-5153A was tested at Eurofins Cerep Panlabs Taiwan, Ltd in the "Hit Profiling Screen", which tested 30 different targets.
| Pharmacokinetic studies
Studies were performed by Pharmalegacy (Shanghai, China), GVK (Hyderabad, India) and Sundia, (Shanghai, China), with local ethics approval. Wistar rats were administered PXS-5153A orally at 10 mg/ kg or intravenously at 5 mg/kg, while C57/BL6 mice received PXS-5153A orally or intravenously at 5 mg/kg. Plasma was analysed for PXS-5153A by high-performance liquid chromatography-mass spectrometry/mass spectrometry (LCMS/MS).
| Collagen oxidation assay
Collagen oxidation assay was based on the release of hydrogen peroxide as previously described 27 and detailed in the supporting infor- 
| NASH-induced liver disease
The study was performed by Stelic MC, Inc. (Tokyo, Japan) with approval from local ethics committee. NASH was established in male C57/BL6 mice by a single subcutaneous injection of 200 μg streptozotocin (Sigma-Aldrich) after birth and with a high fat diet (CLEA Japan) ad libitum after 4 weeks of age (day 28 ± 2) until 14 weeks of age. Mice were orally administered with 10 mg/kg PXS-5153A once daily from 8 to 14 weeks of age. ALT levels were assessed in the plasma. One lobe of the liver tissue was fixed in 10% formalin, stained for Sirius red and the percentage coverage area was measured; HE staining was performed to estimate non-alcoholic fatty liver disease (NAFLD) activity score according to the criteria of Kleiner et al 28 The remainder of the liver was snap frozen and used for protein, hydroxyproline and crosslink analysis.
| Myocardial infarction
The study was performed by CL Laboratory (Baltimore, USA) with approval from the Institutional Animal Care and Use Committee.
Myocardial infarction (MI) was induced in C57/BL6 mice by occluding the left coronary artery. The same surgery but without occluding the left coronary artery was used as a sham control. At 24 hours post-surgery, animals received echocardiography.
Infarcted mice with high cardiac function (FS > 40%) or low cardiac function (FS < 10%) were excluded from the study. The remaining mice were treated q.d., p.o., with 25 mg/kg of PXS-5153A for 4 weeks. At the end of the experiment, echocardiography was performed on mice to assess left ventricular function and remodelling, followed by heart collection. The heart was fixed with 10% formalin. Fibrosis was assessed in the non-infarct area. Fibrotic blue area and whole non-infarct area were measured using computerized planimetry (Image J). The fibrotic area was presented as a percentage of the whole non-infarct area. Three random fields per heart were counted, averaged and a total of 30-45 fields per group were measured.
| RNA isolation and real-time PCR analysis
Total RNA was extracted with the PureLink RNA Mini Kit according to the manufacturer's instructions (Ambion), followed by the cDNA synthesis using SuperScript VILO cDNA Synthesis Kit (Life technologies). Gene expression was measured by the 2 −ΔΔCT method using ABI7500 (Applied Biosystems) with the ABI TaqMan primer sets as specified in the supporting information.
3 | RESULTS
| Development of the LOXL2/LOXL3 inhibitor PXS-5153A
PXS-5153A ( Figure S2 ) is an innovative dual inhibitor of LOXL2/ LOXL3, the design of which was based on biochemistry of the target enzyme(s) coupled with previously gained knowledge of fluoroallylamine-bearing, mechanism-based inhibitors. 29 PXS-5153A exhibited an IC 50 of <40 nmol/L for LOXL2 across all mammalian species tested (Table 1) . PXS-5153A also inhibited human LOXL3 with an IC 50 value of 63 nmol/L. The compound is >40-fold selective for LOXL2 over both LOX and LOXL1 and >700-fold selective over other related amine oxidases. PXS-5153A was found to have little to no activity against a number of additional targets (Table S1) , with the exception of Adrenergic α2A (97%, when tested at 10 μmol/L) and calcium channel L-type, dihydropyridine receptor, rat (80%, when tested at 10 μmol/L).
PXS-5153A was designed to interact with the LTQ (lysine tyrosylquinone) cofactor in the enzymatic pocket of LOXL2 and LOXL3, which, upon elimination of the fluoride-leaving group, leads to a covalently bound enzyme-inhibitor complex. The importance of the leaving group was highlighted by the 20-fold reduced potency displayed by the corresponding des-fluoro analogue (Table S2) . PXS-5153A is a mechanism-based inhibitor that irreversibly blocks enzy- PXS-5153A is a fast acting inhibitor, with enzymatic activity almost entirely blocked within 15 minutes, as judged by the shift in the concentration response curves ( Figure 1A ). In contrast, the racemate of the selective LOXL2 inhibitor of PAT-1251-requires approximately 4 hours to achieve complete inhibition ( Figure S3B ).
The pharmacokinetic (PK) properties of PXS-5153A were investigated in rats and mice and are reported in would be sufficient to achieve long-lasting enzyme inhibition due to the fast acting, irreversible mechanism.
| Inhibition of in vitro collagen oxidation and crosslinking by PXS-5153A
With the successful development of the dual LOXL2/LOXL3 enzymatic inhibitor PXS-5153A, it was feasible to begin exploring the role of these enzymes during the collagen crosslinking process. To confirm the positive effect of the small molecule inhibitor in the initial steps of this process, collagen oxidation was assessed after incubation with enzymatically active rhLOXL2. As expected, rhLOXL2 dose dependently induced oxidation of collagen ( Figure 2A ) with PXS-5153A dose-dependently impeding collagen oxidation ( Figure 2B ).
Given the ability of PXS-5153A to hinder the initial step of crosslinking, it was anticipated that crosslink formation would also be ablated. To confirm this hypothesis, purified collagen was incubated with rhLOXL2 enzyme for 7 days and crosslinks were measured by LCMS/MS. As was formed. 13 Remarkably, mRNA levels of LOXL2 and LOXL3 were substantially increased upon 6-weeks of CCl 4 treatment ( Figure 3A) , which confirmed the suitability of the model for assessing the role of LOXL2/LOXL3.
To verify the induction of fibrosis in these animals, hydroxyproline (HYP) a marker of collagen content was analysed. The CCl 4 -treated control group showed a significant increase in HYP as compared to healthy controls ( Figure 3B) ; while all dosing regimens of PXS-5153A significantly reduced the HYP content by >30%.
Total immature collagen crosslink as well as total mature crosslink quantities were then analysed. There was a significant increase of immature as well as mature crosslinks upon CCl 4 -stimulus compared to healthy animals (4.6 and 2.7-fold increase, respectively; Figure 3C ). animals. Similarly, all groups with PXS-5153A treatment showed F I G U R E 2 Collagen oxidation and crosslinking inhibition by PXS-5153A. rhLOXL2 was incubated with a natural substrate (collagen) and oxidation was analysed using an AR/HRP assay with (A) 375 μg/mL of collagen used as a substrate. (B) Slope from the collagen oxidation assay using 20 nmol/L rhLOXL2 and different concentrations of PXS-5153A at the 20-40 minute time point. 20 nmol/L of rhLOXL2 was added daily to collagen for 5 days. 200 nmol/L of PXS-5153A was pre-incubated with rhLOXL2 for 30 minutes before addition to collagen. Data are presented as means ± standard deviation and differences between groups were assessed using one-way ANOVA followed by Dunnett's test. The pathway dominance (hydroxyallysine or allysine-derived crosslinks) can be determined by calculating the ratio between hydroxylysine:lysine crosslinks and is a potential indicator of fibrotic status. The ratio was elevated in all CCl 4 -treated animals due to increased levels of DHLNL and PYD ( Figure 3D ).
To determine the rate of crosslink formation compared to the secretion of collagen, the quantities of each crosslink was normalized relative to the hydroxyproline content. Upon CCl 4 treatment, the ratio between DHLNL/HYP was increased, indicating that the formation of DHLNL is faster than the synthesis and secretion of collagen, and this effect was reversed by treatment with PXS-5153A (Figure S4A) . In contrast, the ratios between PYD/HYP, HLNL/HYP and DPD/HYP all decreased, demonstrating the slow rate of formation of these crosslinks compared to the fast secretion of collagen (Figure S4B-D) . Data are compared using Student Two-tailed t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to the CCl 4 group; # P < 0.05, ## P < 0.01, In the NASH model, both PYD and DHLNL showed a significant positive correlation compared to the percentage fibrotic, and a modest correlation with the NASH score ( Figure S7A-D) . Sham and n = 12-16 NASH. Data are compared using Student Two-tailed t test. *P < 0.05, **P < 0.01, ***P < 0.001 relative to the NASH group; # P < 0.05, ## P < 0.01, #### P < 0.01 compared with sham control. Effect of PXS-5153A on NASH: (H) representative photomicrographs of the HE stained liver sections (50 and 100X); (I) NAFLD activity score (NAS), calculated according to the criteria of Kleiner (30) . Data are presented as mean values ± SEM for n = 6 Sham and n = 12-16 NASH. Histological scoring analysed using nonparametric Mann-Whitney U test. Data are compared using Student Two-tailed t test. ***P < 0.001, ****P < 0.001 relative to NASH.
#### P < 0.0001 compared with sham control Overall, these results indicate that PYD and DHLNL can be used as predictors of disease severity during liver fibrosis, with levels of PYD showing more significance than those of DHLNL.
| Inhibition of heart fibrosis by PXS-5153A
A number of studies have indicated that inhibition of LOX family members, in particular LOXL2, can positively influence myocardial remodelling, 33, 34 with LOXL2 mRNA expression being highly upregulated upon cardiac disease. 34 As 
| DISCUSSION
Lysyl oxidases have been proposed to play a crucial role in the development of fibrosis owing to their ability to crosslink collagen within the fibrotic matrix. 2 A novel selective LOXL2/LOXL3 dual inhibitor, PXS-5153A, was developed to evaluate the specific role of the enzymatic function of these two enzymes in collagen crosslinking and fibrosis. In line with previous reports, LOXL2 was found to play a significant role in fibrosis, 13, 14 with mRNA upregulation during liver fibrosis. Furthermore, these findings extended to LOXL3, which previously had only been linked to lung fibrosis. On a more fundamental level, the findings of this study confirm that hydroxyallysine-derived crosslinks are a direct result of LOXL2/ LOXL3 enzymatic function. The mechanism by which collagen crosslinks are formed is based on the reactions of allysine or hydroxyallysines present on collagen side-chains with other aldehydes or with unmodified lysine or hydroxylysine residues, resulting in the formation of crosslinks. 7, [9] [10] [11] The availability of hydroxyallysine is the direct result of lysine hydroxylation, through a process driven by lysyl hydroxylases. 35 In bone, tendon, ligaments and cartilage, 36,37 the collagen is | 1767 crosslinked mainly via the hydroxyallysine route, whereas in skin the crosslinks are derived from the allysine route. 38, 39 44, 45 Interestingly, in hypertrophic scars, during the initial stages of wound healing there is a strong preference towards allysine crosslinks, which changes over time to that of the hydroxyallysine crosslinks. 38 Taken together, the findings consistently substantiate that hydroxyallysine crosslinking is the principal pathway involved during fibrosis. These findings are also in agreement with the current study, as it showed the preferential contributions of DHLNL/PYD in CCl 4 induced liver fibrosis as well as NASH induced STZ-high fat diet.
Given that overhydroxylation of lysine is a consequence of increases in the levels of lysyl hydroxylase, 42, [46] [47] [48] it is conceivable that availability of lysyl hydroxylases dictates the pattern of crosslinking during disease.
Even though crosslink maturity as well as allysine/hydroxyallysine pathway ratios have been previously correlated with tissue mechanical properties, 49, 50 this is the first study to correlate hydroxyallysine A number of studies have been useful in confirming the role of lysyl oxidases in controlling tissue stiffness and collagen extractability, 14,51,52 however, they did not provide definite evidence for the correlation between lysyl oxidase enzymatic action and collagen crosslinking. In our current study, analysis of the liver revealed that the content of immature (DHLNL and HLNL) and mature (PYD and DPD) crosslinked collagen was increased upon the induction of liver fibrosis and that dual inhibition of the enzymatic functions of both LOXL2/ LOXL3 reduced formation of these crosslinks. Although a direct comparison of individual crosslinks and liver stiffness was not performed in the current study, the results generated support the concept that difficulty in extractability and increases in tissue stiffness 14, 52 are due to collagen crosslink maturation. Altogether, these results suggest that LOXL2/LOXL3 enzyme-dependent crosslink formation leads to remodelling during fibrosis and, overall, tougher tissue.
Taken together, these results show that LOXL2 and LOXL3 enzymatic functions are key players in the formation of hydroxyallysine derived collagen crosslinks during fibrosis. This study highlights the potential of inhibiting LOXL2/LOXL3 enzymatic activities, for example by use of PXS-5153A, as a novel therapeutic tool for the treatment of diseases that are characterized by abnormal increases in collagen crosslinking.
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